Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf156 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Tomoko Yoshida und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Human Growth Hormone, Hormone Replacement Therapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Context
The consequences of untreated adult growth hormone deficiency (aGHD) among childhood cancer survivors are not well defined. The lack of evidence and socioeconomic factors may contribute to underutilization of growth hormone therapy (GHT) among survivors with aGHD.
Objectives
This work aimed to examine the association of GHT use with socioeconomic factors and to assess the effect of untreated aGHD in survivors using insulin-like growth factor-1 (IGF1) as a marker of GH action.
Methods
A total of 3902 five-year survivors of childhood cancer aged 18 years and older were included. The associations between GHT use and socioeconomic factors (health insurance coverage, income, area deprivation index), and associations between IGF1 levels and prevalences of adverse physical, neurocognitive, and psychosocial outcomes were assessed cross-sectionally by multivariable logistic regression adjusting for potential confounders.
Results
Among 354 survivors with severe aGHD, 9.0% were on GHT. Socioeconomic disadvantages were independently associated with less use of GHT (eg, odds ratio [OR] of GHT use 0.27; 95% CI, 0.08-0.84 for annual household income <$40 000 vs ≥$80 000). The low IGF1 group (z score ≤ −2) experienced significantly higher prevalences of various adverse outcomes compared to the normal IGF1 group (z score >0), including various neurocognitive impairment (eg, verbal reasoning [OR 2.79; 95% CI, 1.95-3.98]), diminished health-related quality of life (eg, physical functioning [1.97; 1.35-2.86]), abnormal glucose metabolism (1.82; 1.21-2.71), and abnormal fat percentage (3.16; 1.98-5.26).
Conclusion
Untreated aGHD potentially contributes to multidimensional adverse outcomes, and GHT may provide health benefits among survivors, though socioeconomic disadvantage may limit their access to GHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Pediatric Medicine-Endocrinology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
- Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Tomoko Yoshida, Yan Chen, Tara M Brinkman, Melissa M Hudson, Yutaka Yasui, Angela Delaney
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Yoshida, T., Baedke, J. L., Wang, H., Chen, Y., Yu, C., Wilson, C. L., Mulrooney, D. A., Dixon, S. B., Huang, I. C., Brinkman, T. M., Krull, K. R., Mostoufi-Moab, S., Martínez, J. M., Ness, K. K., Hudson, M. M., Yasui, Y., & Delaney, A. (2025). Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf156
Vancouver
Yoshida T, Baedke JL, Wang H, Chen Y, Yu C, Wilson CL, et al. Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf156
BibTeX
@article{Yoshida2025,
author = {Yoshida, Tomoko and Baedke, Jessica L and Wang, Huiqi and Chen, Yan and Yu, Christine and Wilson, Carmen L and Mulrooney, Daniel A and Dixon, Stephanie B and Huang, I Chan and Brinkman, Tara M and Krull, Kevin R and Mostoufi-Moab, Sogol and Martínez, José Miguel and Ness, Kirsten K and Hudson, Melissa M and Yasui, Yutaka and Delaney, Angela},
title = {Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf156}
}
EUVIMED